false 0000880242 0000880242 2024-06-13 2024-06-13
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
 
Date of Report (Date of earliest event reported): June 13, 2024
 
BioLargo, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
000-19709
 
65-0159115
(State or other jurisdiction
of incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification No.)
 
 
14921 Chestnut St., Westminster, California
 
92683
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (888) 400-2863
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
BLGO
OTCQB
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

 
 
Item 7.01 Regulation FD Disclosure.
 
BioLargo, Inc., intends to present the slides attached as Exhibit 99.1, which are incorporated herein by reference, at its annual stockholder meeting on June 13, 2024, at 10:00 am Pacific Time.
 
The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the presentation slides attached as Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the information under the heading “Safe Harbor Act” in Exhibit 99.1 attached hereto.
 
Item 9.01. Financial Statements and Exhibits.
 
(d)         Exhibits.
 
   
Exhibit
No.
Description
99.1
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
                 
Date: June 13, 2024
     
BIOLARGO, INC.
         
           
By:
 
/s/ Dennis P. Calvert
               
Dennis P. Calvert
               
President and Chief Executive Officer
 
 
 
 
 

Exhibit 99.1

 

 

 

slide01.jpg

 

 

 

 
slide02.jpg

 

 

 
slide03.jpg

 

 

 
slide04.jpg

 

 

 
slide05.jpg

 

 

 
slide06.jpg

 

 

 
slide07.jpg

 

 

 
slide08.jpg

 

 

 
slide09.jpg

 

 

 
slide10.jpg

 

 

 
slide11.jpg

 

 

 
slide12.jpg

 

 

 
slide13.jpg

 

 

 
slide14.jpg

 

 

 
slide15.jpg

 

 

 
slide16.jpg

 

 

 
slide17.jpg

 

 

 
slide18.jpg

 

 

 
slide19.jpg

 

 

 
slide20.jpg

 

 

 
slide21.jpg

 

 

 
slide22.jpg

 

 

 
slide23.jpg

 

 

 
slide24.jpg

 

 

 
slide25.jpg

 

 

 
slide26.jpg

 

 

 
slide27.jpg

 

 

 
slide28.jpg

 

 

 
slide29.jpg

 

 

 
slide30.jpg

 

 

 
slide31.jpg

 

 

 
slide32.jpg

 

 

 
slide33.jpg

 

 

 
slide34.jpg

 

 

 
slide35.jpg

 

 

 
slide36.jpg

 

 

 
slide37.jpg

 

 

 
slide38.jpg

 

 

 
slide39.jpg

 

 

 
slide40.jpg

 

 

 
slide41.jpg

 

 

 
slide42.jpg

 

 

 
slide43.jpg

 

 

 
slide44.jpg

 

 

 
slide45.jpg

 

 

 
slide46.jpg

 

 

 
slide47.jpg

 

 

 
slide48.jpg

 

 

 
slide49.jpg

 

 
v3.24.1.1.u2
Document And Entity Information
Jun. 13, 2024
Document Information [Line Items]  
Entity, Registrant Name BioLargo, Inc.
Document, Type 8-K
Document, Period End Date Jun. 13, 2024
Entity, Incorporation, State or Country Code DE
Entity, File Number 000-19709
Entity, Tax Identification Number 65-0159115
Entity, Address, Address Line One 14921 Chestnut St.
Entity, Address, City or Town Westminster
Entity, Address, State or Province CA
Entity, Address, Postal Zip Code 92683
City Area Code 888
Local Phone Number 400-2863
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol BLGO
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0000880242

BioLargo (QX) (USOTC:BLGO)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025 Plus de graphiques de la Bourse BioLargo (QX)
BioLargo (QX) (USOTC:BLGO)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025 Plus de graphiques de la Bourse BioLargo (QX)